Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The Prime Minister announced that 21st June onwards, the Government of India will provide free vaccines to all Indian citizens above 18 years of age
The company is doubling its chemistry research capacity that should commission by Q2'FY22
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
Subscribe To Our Newsletter & Stay Updated
